Variant Aldehyde Dehydrogenase 2 (ALDH2*2) as a Risk Factor for Mechanical LA Substrate Formation and Atrial Fibrillation with Modest Alcohol Consumption in Ethnic Asians
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Subjects
2.2. Conventional Cardiac Structural and Diastolic Functional Assessment
2.3. Assessment of the PR Interval Using Body Surface Electrocardiography (ECG)
2.4. Assessment of Phasic LA Functional Imaging Using Novel LA Deformational Markers
2.5. CHARGE-AF Score Calculation
2.6. Assessment of Circulating Aldehyde By-Product 4-Hydroxynonenal (4-HNE)
2.7. Definitions of Prevalent AF
2.8. Statistical Analysis
3. Results
3.1. Baseline Demographics
3.2. Association of ALDH2 Polymorphism with Novel Functional LA Indices in Modest Alcohol Consumers
3.3. Association of ALDH2 Polymorphism with Prevalent AF in Modest Alcohol Consumers
4. Discussion
4.1. Association of Patterns of Alcohol Consumption with Atrial Substrate Vulnerability and AF
4.2. ALDH2 Polymorphism Modifies the Association of Alcohol Use with LA Mechanical Substrate Vulnerability
4.3. Novel LA Mechanical Substrate as a Surrogate Marker for AF Vulnerability
5. Limitations
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Isse, T.; Matsuno, K.; Oyama, T.; Kitagawa, K.; Kawamoto, T. Aldehyde Dehydrogenase 2 Gene Targeting Mouse Lacking Enzyme Activity Shows High Acetaldehyde Level in Blood, Brain, and Liver after Ethanol Gavages. Alcohol. Clin. Exp. Res. 2005, 29, 1959–1964. [Google Scholar] [CrossRef]
- Chen, C.-H.; Ferreira, J.C.B.; Gross, E.R.; Mochly-Rosen, D. Targeting Aldehyde Dehydrogenase 2: New Therapeutic Opportunities. Physiol. Rev. 2014, 94, 1–34. [Google Scholar] [CrossRef] [Green Version]
- Gross, E.R.; Zambelli, V.O.; Small, B.A.; Ferreira, J.C.B.; Chen, C.-H.; Mochly-Rosen, D. A Personalized Medicine Approach for Asian Americans with the Aldehyde Dehydrogenase 2*2 Variant. Annu. Rev. Pharmacol. Toxicol. 2015, 55, 107–127. [Google Scholar] [CrossRef] [Green Version]
- Wang, J.; Wang, H.; Hao, P.; Xue, L.; Wei, S.; Zhang, Y.; Chen, Y. Inhibition of Aldehyde Dehydrogenase 2 by Oxidative Stress Is Associated with Cardiac Dysfunction in Diabetic Rats. Mol. Med. 2010, 17, 172–179. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Brocker, C.; Koppaka, V.; Chen, Y.; Jackson, B.C.; Matsumoto, A.; Thompson, D.C.; Vasiliou, V. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilicstress. Free. Radic. Biol. Med. 2013, 56, 89–101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Doser, T.A.; Turdi, S.; Thomas, D.P.; Epstein, P.; Li, S.-Y.; Ren, J. Transgenic Overexpression of Aldehyde Dehydrogenase-2 Rescues Chronic Alcohol Intake–Induced Myocardial Hypertrophy and Contractile Dysfunction. Circulation 2009, 119, 1941–1949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larsson, S.C.; Drca, N.; Wolk, A. Alcohol Consumption and Risk of Atrial Fibrillation: A prospective study and dose-response me-ta-analysis. J. Am. Coll. Cardiol. 2014, 64, 281–289. [Google Scholar] [CrossRef]
- Voskoboinik, A.; Prabhu, S.; Ling, L.-H.; Kalman, J.M.; Kistler, P.M. Alcohol and Atrial Fibrillation: A Sobering Review. J. Am. Coll. Cardiol. 2016, 68, 2567–2576. [Google Scholar] [CrossRef] [PubMed]
- Csengeri, D.; Sprünker, N.-A.; Di Castelnuovo, A.; Niiranen, T.; Vishram-Nielsen, J.K.; Costanzo, S.; Söderberg, S.; Jensen, S.M.; Vartiainen, E.; Donati, M.B.; et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. Eur. Heart J. 2021, 42, 1170–1177. [Google Scholar] [CrossRef]
- Voskoboinik, A.; Kalman, J.M.; De Silva, A.; Nicholls, T.; Costello, B.; Nanayakkara, S.; Prabhu, S.; Stub, D.; Azzopardi, S.; Vizi, D.; et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N. Engl. J. Med. 2020, 382, 20–28. [Google Scholar] [CrossRef]
- Djoussé, L.; Gaziano, J.M. Alcohol consumption and heart failure: A systematic review. Curr. Atheroscler. Rep. 2008, 10, 117–120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bazal, P.; Gea, A.; Martínez-González, M.; Salas-Salvadó, J.; Asensio, E.; Muñoz-Bravo, C.; Fiol, M.; Muñoz, M.-A.; Lapetra, J.; Serra-Majem, L.; et al. Mediterranean alcohol-drinking pattern, low to moderate alcohol intake and risk of atrial fibrillation in the PREDIMED study. Nutr. Metab. Cardiovasc. Dis. 2019, 29, 676–683. [Google Scholar] [CrossRef] [PubMed]
- Hung, C.-L.; Gonçalves, A.; Lai, Y.-J.; Lai, Y.-H.; Sung, K.-T.; Lo, C.-I.; Liu, C.-C.; Kuo, J.-Y.; Hou, C.J.-Y.; Chao, T.-F.; et al. Light to Moderate Habitual Alcohol Consumption Is Associated with Subclinical Ventricular and Left Atrial Mechanical Dysfunction in an Asymptomatic Population: Dose-Response and Propensity Analysis. J. Am. Soc. Echocardiogr. 2016, 29, 1043–1051.e4. [Google Scholar] [CrossRef] [PubMed]
- Hung, C.-L.; Chang, S.-C.; Chang, S.-H.; Chi, P.-C.; Lai, Y.-J.; Wang, S.-W.; Wu, Y.-J.; Yeh, H.-I.; Lin, S.-J.; Chen, C.-H.; et al. Genetic Polymorphisms of Alcohol Metabolizing Enzymes and Alcohol Consumption are Associated With Asymptomatic Cardiac Remodeling and Subclinical Systolic Dysfunction in Large Community-Dwelling Asians. Alcohol Alcohol. 2017, 52, 638–646. [Google Scholar] [CrossRef]
- Voskoboinik, A.; McDonald, C.; Chieng, D.; O’Brien, J.; Gutman, S.; Ngu, P.; Sugumar, H.; Wong, G.; Kalman, J.M.; Taylor, A.J.; et al. Acute electrical, autonomic and structural effects of binge drinking: Insights into the ‘holiday heart syndrome’. Int. J. Cardiol. 2021, 331, 100–105. [Google Scholar] [CrossRef]
- Magnani, J.W.; Wang, N.; Nelson, K.P.; Connelly, S.; Deo, R.; Rodondi, N.; Schelbert, E.B.; Garcia, M.E.; Phillips, C.L.; Shlipak, M.G.; et al. Electrocardiographic PR Interval and Adverse Outcomes in Older Adults. Circ. Arrhythmia Electrophysiol. 2013, 6, 84–90. [Google Scholar] [CrossRef] [Green Version]
- Liao, J.-N.; Chao, T.-F.; Kuo, J.-Y.; Sung, K.-T.; Tsai, J.-P.; Lo, C.-I.; Lai, Y.-H.; Su, C.-H.; Hung, C.-L.; Yeh, H.-I.; et al. Age, Sex, and Blood Pressure-Related Influences on Reference Values of Left Atrial Deformation and Mechanics From a Large-Scale Asian Population. Circ. Cardiovasc. Imaging 2017, 10. [Google Scholar] [CrossRef] [Green Version]
- Christophersen, I.E.; Yin, X.; Larson, M.G.; Lubitz, S.A.; Magnani, J.W.; McManus, D.D.; Ellinor, P.; Benjamin, E.J. A comparison of the CHARGE–AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am. Heart J. 2016, 178, 45–54. [Google Scholar] [CrossRef] [Green Version]
- Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.-A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Devel-oped with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2020, 42, 373–498. [Google Scholar] [CrossRef]
- Ettinger, P.O.; Wu, C.F.; De La Cruz, C.; Weisse, A.B.; Ahmed, S.S.; Regan, T.J. Arrhythmias and the “Holiday Heart”: Alcoholassociated cardiac rhythm disorders. Am. Heart J. 1978, 95, 555–562. [Google Scholar] [CrossRef]
- Sutanto, H.; Cluitmans, M.J.; Dobrev, D.; Volders, P.G.; Bébarová, M.; Heijman, J. Acute effects of alcohol on cardiac electrophysiology and arrhythmogenesis: Insights from multiscale in silico analyses. J. Mol. Cell. Cardiol. 2020, 146, 69–83. [Google Scholar] [CrossRef]
- Yan, J.; Thomson, J.K.; Zhao, W.; Gao, X.; Huang, F.; Chen, B.; Liang, Q.; Song, L.-S.; Fill, M.; Ai, X. Role of Stress Kinase JNK in Binge Alcohol-Evoked Atrial Arrhythmia. J. Am. Coll. Cardiol. 2018, 71, 1459–1470. [Google Scholar] [CrossRef]
- Qiao, Y.; Shi, R.; Hou, B.; Wu, L.; Zheng, L.; Ding, L.; Chen, G.; Zhang, S.; Yao, Y. Impact of Alcohol Consumption on Substrate Remodeling and Ablation Outcome of Paroxysmal Atrial Fibrillation. J. Am. Heart Assoc. 2015, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whitman, I.R.; Agarwal, V.; Nah, G.; Dukes, J.W.; Vittinghoff, E.; Dewland, T.A.; Marcus, G.M. Alcohol Abuse and Cardiac Disease. J. Am. Coll. Cardiol. 2017, 69, 13–24. [Google Scholar] [CrossRef] [PubMed]
- Kodama, S.; Saito, K.; Tanaka, S.; Horikawa, C.; Saito, A.; Heianza, Y.; Anasako, Y.; Nishigaki, Y.; Yachi, Y.; Iida, K.T.; et al. Alcohol Consumption and Risk of Atrial Fibrillation: A Meta-Analysis. J. Am. Coll. Cardiol. 2011, 57, 427–436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Habuchi, Y.; Furukawa, T.; Tanaka, H.; Lu, L.-L.; Morikawa, J.; Yoshimura, M. Ethanol inhibition of Ca2+ and Na+ currents in the guinea-pig heart. Eur. J. Pharmacol. Environ. Toxicol. Pharmacol. 1995, 292, 143–149. [Google Scholar] [CrossRef]
- Preedy, V.R.; Siddiq, T.; Why, H.; Richardson, P.J. The deleterious effects of alcohol on the heart include protein turnover. Alcohol Alcoholism 1994, 29, 141–147. [Google Scholar]
- Kaplan, P.; Tatarkova, Z.; Račay, P.; Lehotský, J.; Pavlíková, M.; Dobrota, D. Oxidative modifications of cardiac mitochondria and inhibition of cytochromecoxidase activity by 4-hydroxynonenal. Redox Rep. 2007, 12, 211–218. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.-H.; Ferreira, J.C.B.; Mochly-Rosen, D. ALDH2 and Cardiovascular Disease. Aldehyde Dehydrogen. 2019, 1193, 53–67. [Google Scholar] [CrossRef]
- Awtry, E.; Philippides, G.J. Alcoholic and Cocaine-Associated Cardiomyopathies. Prog. Cardiovasc. Dis. 2010, 52, 289–299. [Google Scholar] [CrossRef]
- Lang, C.H.; Frost, R.A.; Summer, A.D.; Vary, T.C. Molecular mechanisms responsible for alcohol-induced myopathy in skeletal muscle and heart. Int. J. Biochem. Cell Biol. 2005, 37, 2180–2195. [Google Scholar] [CrossRef]
- McManus, D.D.; Yin, X.; Gladstone, R.; Vittinghoff, E.; Vasan, R.S.; Larson, M.G.; Benjamin, E.J.; Marcus, G.M. Alcohol Consumption, Left Atrial Diameter, and Atrial Fibrillation. J. Am. Heart Assoc. 2016, 5. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Forman, H.J. Signaling by 4-hydroxy-2-nonenal: Exposure protocols, target selectivity and degradation. Arch. Biochem. Biophys. 2016, 617, 145–154. [Google Scholar] [CrossRef] [Green Version]
- Voskoboinik, A.; Costello, B.T.; Kalman, E.; Prabhu, S.; Sugumar, H.; Wong, G.; Nalliah, C.; Ling, L.-H.; McLellan, A.; Hettige, T.; et al. Regular Alcohol Consumption Is Associated With Impaired Atrial Mechanical Function in the Atrial Fibrillation Population. JACC Clin. Electrophysiol. 2018, 4, 1451–1459. [Google Scholar] [CrossRef] [PubMed]
- Hsu, L.-A.; Tsai, F.-C.; Yeh, Y.-H.; Chang, C.-J.; Kuo, C.-T.; Chen, W.-J.; Tsai, H.-Y.; Chang, G.-J. Aldehyde Dehydrogenase 2 Ameliorates Chronic Alcohol Consumption-Induced Atrial Fibrillation through Detoxification of 4-HNE. Int. J. Mol. Sci. 2020, 21, 6678. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.-H.; Sun, L.; Mochly-Rosen, D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc. Res. 2010, 88, 51–57. [Google Scholar] [CrossRef] [Green Version]
- Agarwal, D.P.; Harada, S.; Goedde, H.W. Racial Differences in Biological Sensitivity to Ethanol: The Role of Alcohol Dehydrogenase and Aldehyde Dehydrogenase Isozymes. Alcohol. Clin. Exp. Res. 2008, 5, 12–16. [Google Scholar] [CrossRef] [PubMed]
- Brooks, P.J.; Enoch, M.-A.; Goldman, D.; Li, T.-K.; Yokoyama, A. The Alcohol Flushing Response: An Unrecognized Risk Factor for Esophageal Cancer from Alcohol Consumption. PLoS Med. 2009, 6, e1000050. [Google Scholar] [CrossRef] [PubMed]
- Wenzel, P.; Müller, J.; Zurmeyer, S.; Schuhmacher, S.; Schulz, E.; Oelze, M.; Pautz, A.; Kawamoto, T.; Wojnowski, L.; Kleinert, H.; et al. ALDH-2 deficiency increases cardiovascular oxidative stress---Evidence for indirect antioxidative properties. Biochem. Biophys. Res. Commun. 2008, 367, 137–143. [Google Scholar] [CrossRef] [PubMed]
- Babapoor-Farrokhran, S.; Gill, D.; Alzubi, J.; Mainigi, S.K. Atrial fibrillation: The role of hypoxia-inducible factor-1-regulated cytokines. Mol. Cell. Biochem. 2021, 476, 2283–2293. [Google Scholar] [CrossRef]
- Everett, B.M.; Cook, N.R.; Conen, D.; Chasman, D.I.; Ridker, P.M.; Albert, C. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur. Heart J. 2013, 34, 2243–2251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, Y.G.; Han, K.-D.; Choi, J.-I.; Boo, K.Y.; Kim, D.Y.; Lee, K.-N.; Shim, J.; Kim, J.S.; Kim, Y.-H. Frequent drinking is a more important risk factor for new-onset atrial fibrillation than binge drinking: A nationwide population-based study. Europace 2019, 22, 216–224. [Google Scholar] [CrossRef] [PubMed]
- Deferm, S.; Bertrand, P.B.; Churchill, T.W.; Sharma, R.; Vandervoort, P.M.; Schwamm, L.H.; Sanborn, D.M.Y. Left Atrial Mechanics Assessed Early during Hospitalization for Cryptogenic Stroke Are Associated with Occult Atrial Fibrillation: A Speckle-Tracking Strain Echocardiography Study. J. Am. Soc. Echocardiogr. 2020, 34, 156–165. [Google Scholar] [CrossRef] [PubMed]
- Yamada, A.; Hashimoto, N.; Fujito, H.; Hatta, T.; Saito, Y.; Otsuka, N.; Wakamatsu, Y.; Arai, M.; Watanabe, R.; Kurokawa, S.; et al. Comprehensive assessment of left atrial and ventricular remodeling in paroxysmal atrial fibrillation by the cardiovascular magnetic resonance myocardial extracellular volume fraction and feature tracking strain. Sci. Rep. 2021, 11, 1–12. [Google Scholar] [CrossRef] [PubMed]
Drinking Behavior | (Habitual Drinkers) (n = 193) | |||||
---|---|---|---|---|---|---|
Non-Drinkers (n = 56) | Habitual Drinkers (n = 193) | p-Value | ALDH2 Polymorphism (−) (n = 135) | ALDH2 Polymorphism (+) (n = 58) | p-Value (ANOVA) | |
Demographics/anthropometrics | ||||||
Age, years | 51.7 ± 10.0 | 51.4 ± 10.1 | 0.649 | 52.1 ± 10.4 | 49.5 ± 9.1 | 0.25 |
Female, % | 20 (34.5) | 29 (15.0) | 0.002 | 20 (14.8) | 9 (15.5) | 0.007 |
Body height, cm | 164.2 ± 9.1 | 167.7 ± 7.5 | 0.004 | 167.3 ± 7.5 * | 168.6 ± 7.4 * | 0.01 |
BMI, kg/m2 | 25.4 ± 3.5 | 25.9 ± 4.3 | 0.412 | 25.9 ± 4.5 | 25.9 ± 4.1 | 0.67 |
Waist circumference, cm | 85.6 ± 10.1 | 88.1 ± 10.2 | 0.113 | 86.78 ± 10.23 | 88.69 ± 10.30 | 0.23 |
Systolic blood pressure, mmHg | 129.7 ± 16.4 | 135.3 ± 18.4 | 0.048 | 137.1 ± 18.4 * | 130.3 ± 17.5 # | 0.008 |
Diastolic blood pressure, mmHg | 79.5 ± 11.3 | 82.8 ± 11.3 | 0.052 | 84.0 ± 11.2 * | 80.4 ± 11.2 | 0.019 |
Pulse rate, beats/min | 73.1 ± 12.9 | 72.7 ± 10.8 | 0.78 | 72.7 ± 10.6 | 72.5 ± 11.6 | 0.95 |
CHARGE-AF score | 10.5 ± 1.1 | 10.8 ± 1.2 | 0.048 | 10.9 ± 1.1 * | 10.5 ± 1.2 | 0.013 |
Alcohol consumption information | ||||||
Binge drinking, % | 2 (3.6) | 60 (31.1) | <0.001 | 43 (31.9) | 17 (29.3) | <0.001 |
Daily alcohol intake, g/day ‡ | 0 [0~0] | 14.1 [7.6~28.6] | <0.001 | 14.3 [8.3~28.6] * | 12.3 [6.3~30.7] * | <0.001 |
Daily drinks, per day | 0 [0~0] | 1.2 [0.6~2.4] | <0.001 | 1.2 [0.7~2.4] * | 1.0 [0.5~2.6] * | <0.001 |
Alcohol use duration, years | 0 [0~0] | 16.0 [5.0~30.0] | <0.001 | 20.0 [5.0~30.0] * | 15.0 [5.0~30.0] * | <0.001 |
4-HNE level, μg/mL | 34.2 ± 7.7 | 38.6 ± 9.5 | 0.002 | 36.6 ± 7.1 * | 43.3 ± 12.5 *,# | <0.001 |
Medical history | ||||||
Smoking status | <0.001 | <0.001 | ||||
Non-smoker, % | 43 (76.8) | 74 (38.3) | 48 (35.6) | 26 (44.8) | ||
Active smoker, % | 6 (10.7) | 89 (46.1) | 69 (51.1) | 20 (34.5) | ||
Prior smoker, % | 7 (12.5) | 30 (15.5) | 18 (13.3) | 12 (20.7) | ||
Hypertension, % | 10 (17.9) | 89 (46.1) | <0.001 | 71 (52.6) | 18 (31.0) | <0.001 |
Diabetes, % | 11 (19.6) | 48 (24.9) | 0.42 | 29 (21.5) | 19 (32.8) | 0.17 |
Hyperlipidemia treatment, % | 1 (1.8) | 20 (10.4) | 0.042 | 15 (11.1) | 5 (8.6) | 0.11 |
CAD, % | 0 (0.0) | 17 (8.8) | 0.021 | 10 (7.4) | 7 (12.1) | 0.035 |
CVD, % | 0 (0.0) | 21 (10.9) | 0.009 | 13 (9.6) | 8 (13.8) | 0.023 |
Biochemical data, % | ||||||
Hemoglobin, g/dL | 14.26 ± 1.92 | 14.47 ± 1.45 | 0.39 | 14.45 ± 1.43 | 14.51 ± 1.50 | 0.66 |
Fasting sugar, mg/dL | 107.2 ± 29.5 | 109.1 ± 32.2 | 0.69 | 105.6 ± 19.8 | 104.1 ± 23.7 | 0.88 |
Total cholesterol, mg/dL | 195.2 ± 29.7 | 201.0 ± 37.7 | 0.30 | 205.2 ± 39.6 | 191.2 ± 31.2 # | 0.03 |
HDL-c, mg/dL | 53.4 ± 14.3 | 53.0 ± 15.8 | 0.86 | 54.0 ± 15.3 | 50.9 ± 16.8 | 0.47 |
eGFR, mL/min/1.73m2 | 87.0 ± 18.3 | 93.4 ± 22.3 | 0.05 | 92.13 ± 21.32 | 95.11 ± 22.07 | 0.11 |
Non-Drinkers (n = 56) | Habitual Drinkers (n = 193) | p-Value | (Habitual Drinkers) ALDH2 Polymorphism (−) (n = 135) | (Habitual Drinkers) ALDH2 Polymorphism (+) (n = 58) | p-Value | |
---|---|---|---|---|---|---|
Cardiac structure and function | ||||||
Septal wall thickness, cm | 8.8 ± 1.3 | 9.3 ± 1.3 | 0.013 | 9.3 ± 1.3 | 9.4 ± 1.3 | 0.039 |
Posterior wall thickness, cm | 8.9 ± 1.2 | 9.3 ± 1.3 | 0.027 | 9.2 ± 1.2 | 9.4 ± 1.5 * | 0.048 |
Internal diameter (diastolic), cm | 46.1 ± 4.2 | 47.0 ± 4.0 | 0.18 | 46.8 ± 4.2 | 47.4 ± 3.5 | 0.25 |
Mitral inflow E/A | 1.16 ± 0.31 | 1.18 ± 0.47 | 0.75 | 1.16 ± 0.48 | 1.23 ± 0.46 | 0.58 |
LV mass index, kg/m2 | 71.8 ± 15.0 | 76.1 ± 16.0 | 0.074 | 75.6 ± 16.4 | 77.4 ± 15.2 | 0.16 |
Myocardial e’ (average), cm/sec | 8.6 ± 2.1 | 8.3 ± 2.2 | 0.31 | 8.2 ± 2.2 | 8.4 ± 2.1 | 0.51 |
IVRT, ms | 93.7 ± 20.8 | 88.8 ± 16.6 | 0.068 | 89.7 ± 17.8 | 86.8 ± 13.2 | 0.11 |
LV E/e’ | 8.0 ± 1.7 | 8.4 ± 2.5 | 0.29 | 8.3 ± 2.3 | 8.7 ± 3.0 | 0.29 |
LA electromechanical parameters | ||||||
PR interval, ms | 152.9 ± 19.7 | 167.2 ± 23.9 | <0.001 | 164.0 ± 23.8 * | 174.4 ± 22.9 *,# | <0.001 |
LA volume (max), mL | 36.8 ± 12.1 | 40.5 ± 13.9 | 0.07 | 38.7 ± 15.0 | 44.2 ± 13.2 *,# | 0.007 |
LA emptying fraction (LAEF), % | 43.6 ± 7.8 | 44.2 ± 8.2 | 0.66 | 44.8 ± 8.3 | 42.6 ± 7.6 | 0.19 |
LA volume index, mL/m2 | 19.4 ± 6.3 | 20.4 ± 6.4 | 0.30 | 19.7 ± 6.7 | 22.1 ± 5.5 | 0.036 |
PALS, % | 35.1 ± 6.0 | 30.9 ± 6.2 | <0.001 | 32.0 ± 6.1 * | 28.2 ± 5.5 *,# | <0.001 |
LA reservoir function, 1/s | 1.59 ± 0.30 | 1.33 ± 0.27 | <0.001 | 1.38 ± 0.25 * | 1.22 ± 0.28 *,# | <0.001 |
LA conduit function, 1/s | 1.58 ± 0.51 | 1.38 ± 0.54 | 0.01 | 1.48 ± 0.54 | 1.13 ± 0.46 *,# | <0.001 |
LA booster pump function, 1/s | 2.13 ± 0.50 | 1.88 ± 0.58 | 0.003 | 1.98 ± 0.55 | 1.62 ± 0.57 *,# | <0.001 |
Non-Drinkers (n = 56) | (Habitual Drinkers) ALDH2 Polymorphism (−) (n = 135) | (Habitual Drinkers) ALDH2 Polymorphism (+) (n = 58) | |
---|---|---|---|
Cardiac structure and function | |||
Septal wall thickness, cm | (Reference) | 0.22 (−0.19, 0.63) | 0.37 (−0.08, 0.82) |
Posterior wall thickness, cm | ― | 0.01 (−0.39, 0.42) | 0.29 (−0.16, 0.74) |
Internal diameter (diastolic), cm | ― | −0.33 (−1.59, 0.94) | 0.39 (−1.01, 1.79) |
Mitral inflow E/A | ― | 0.10 (−0.03, 0.24) | 0.10 (−0.05, 0.24) |
LV mass index, kg/m2 † | ― | 0.27 (−4.97, 5.52) | 3.55 (−2.27, 9.36) |
Myocardial e’ (average), cm/sec | ― | 0.11 (−0.44, 0.65) | −0.15 (−0.75, 0.45) |
IVRT, ms | ― | −2.5 (−8.5, 3.6) | −5.3 (−12.0, 1.4) |
LV E/e’ | ― | 0.3 (−0.4, 1.1) | 0.9 (0.1, 1.8) |
LA electromechanical parameters | |||
PR interval, ms | (Reference) | 8.5 (0.7, 16.2) * | 21.2 (12.6, 29.8) *,# |
LA volume (max), mL | ― | 2.5 (−1.7, 6.7) | 7.5 (2.8, 12.2) *,# |
LA emptying fraction (LAEF), % | ― | 0.97 (−1.88, 3.82) | −1.15 (−4.31, 2.00) |
LA volume index, mL/m2 † | ― | 0.9 (−1.3, 3.0) | 3.2 (0.8, 5.6) * |
PALS, % | ― | −2.2 (−4.2, −0.4) * | −6.3 (−8.5, −4.2) *,# |
LA reservoir function, 1/s | ― | −0.18 (−0.28, −0.09) * | −0.38 (−0.49, −0.28) *,# |
LA conduit function, 1/s | ― | −0.001 (−0.15, 0.15) | −0.45 (−0.62, −0.28) *,# |
LA booster pump function, 1/s | ― | −0.08 (−0.27, 0.11) | −0.49 (−0.70, −0.28) *,# |
Prevalent AF | Non-Drinkers (n = 56) | (Habitual Drinkers) ALDH2 Polymorphism (−) (n = 135) | (Habitual Drinkers) ALDH2 Polymorphism (+) (n = 58) |
---|---|---|---|
Number of AF events | 1 (1.8%) | 15 (11.1%) | 9 (15.5%) |
Univariate model, OR (standard error (SE)) | |||
(Reference) | 6.9 (7.19), p = 0.065 | 10.1 (10.8), p = 0.031 | |
Multivariate model, OR (standard error (SE)) | |||
Model adjusted for CHARGE-AF | (Reference) | 5.6 (6.11), p = 0.11 | 12.7 (14.3), p = 0.024 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hung, C.-L.; Sung, K.-T.; Chang, S.-C.; Liu, Y.-Y.; Kuo, J.-Y.; Huang, W.-H.; Su, C.-H.; Liu, C.-C.; Tsai, S.-Y.; Liu, C.-Y.; et al. Variant Aldehyde Dehydrogenase 2 (ALDH2*2) as a Risk Factor for Mechanical LA Substrate Formation and Atrial Fibrillation with Modest Alcohol Consumption in Ethnic Asians. Biomolecules 2021, 11, 1559. https://doi.org/10.3390/biom11111559
Hung C-L, Sung K-T, Chang S-C, Liu Y-Y, Kuo J-Y, Huang W-H, Su C-H, Liu C-C, Tsai S-Y, Liu C-Y, et al. Variant Aldehyde Dehydrogenase 2 (ALDH2*2) as a Risk Factor for Mechanical LA Substrate Formation and Atrial Fibrillation with Modest Alcohol Consumption in Ethnic Asians. Biomolecules. 2021; 11(11):1559. https://doi.org/10.3390/biom11111559
Chicago/Turabian StyleHung, Chung-Lieh, Kuo-Tzu Sung, Shun-Chuan Chang, Yen-Yu Liu, Jen-Yuan Kuo, Wen-Hung Huang, Cheng-Huang Su, Chuan-Chuan Liu, Shin-Yi Tsai, Chia-Yuan Liu, and et al. 2021. "Variant Aldehyde Dehydrogenase 2 (ALDH2*2) as a Risk Factor for Mechanical LA Substrate Formation and Atrial Fibrillation with Modest Alcohol Consumption in Ethnic Asians" Biomolecules 11, no. 11: 1559. https://doi.org/10.3390/biom11111559
APA StyleHung, C.-L., Sung, K.-T., Chang, S.-C., Liu, Y.-Y., Kuo, J.-Y., Huang, W.-H., Su, C.-H., Liu, C.-C., Tsai, S.-Y., Liu, C.-Y., Lee, A.-S., Pan, S.-H., Wang, S.-W., Hou, C. J.-Y., Hung, T.-C., & Yeh, H.-I. (2021). Variant Aldehyde Dehydrogenase 2 (ALDH2*2) as a Risk Factor for Mechanical LA Substrate Formation and Atrial Fibrillation with Modest Alcohol Consumption in Ethnic Asians. Biomolecules, 11(11), 1559. https://doi.org/10.3390/biom11111559